Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NMD-712
- Development stage
- Preclinical
- Lead developer
- NMD Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NMD-712 is an orally bioavailable, small molecule inhibitor of the skeletal muscle-specific chloride ion channel 1 (ClC-1). Developed by NMD Pharma, NMD-712 acts by partially inhibiting ClC-1 receptors, which reduces the threshold required to trigger a muscle fiber action potential and improves neuromuscular transmission. It is being investigated preclinically for the treatment of neuromuscular disorders, including congenital myasthenic syndromes (CMS) such as Agrn-CMS and ColQ-CMS, as well as multiple sclerosis and other conditions characterized by neuromuscular junction transmission failure.
- Other names
- (S)-2-(4-bromophenoxy)butyric acid(S)-2-(p-bromophenoxy)butyric acid
02
Targets
Beyond the preview
Go deeper on NMD-712.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NMD-712.
Work on NMD-712? Claim this page to correct or add information. Claim this page